The U.S. International Trade Commission is soon to make a ruling that will determine whether the No. 1 botulinum toxin (BTX) maker Allergan will be able to maintain its 70 percent market share in the U.S. Last year, Korean BTX manufacturer Medytox and its U.S. partner Allergan filed a complaint with the ITC that Daewoong Pharmaceutical and its partner firm Evolus stole the strain of Medytox’s botu
The Korean government recently lifted the alert level to the highest in the four-tiered system to prevent the spread of the new coronavirus, but some critics said the move was too hasty. Critics said China, where the first confirmed case of the COVID-19 infection occurred, did not declare the highest alert level across the country. Just because new confirmed cases spiked centering mostly on th
In the wake of the ranitidine recall, other antiulcer “tidine-class” drugs, proton-pump inhibitors (PPIs), and various mucosal protective agents have enjoyed sales growth, industry data showed.Artemisia extract-based drugs, led by Dong-A ST’s Stillen Tab., recorded a particularly rapid sales expansion in two months after the ranitidine ban. According to U-BIST data, sales of antiulcer med
Investors are rushing to bet on new drug development, which is often called the goose that lays golden eggs. The government picked the biohealth industry as one of the future growth industries and vowed to support the sector aggressively. In this situation, many domestic drugmakers and biotech venture firms increasingly joined new drug development to target the global market. However, some compani
As an online video claiming that dog dewormer fenbendazole could cure cancer went viral, cancer patients conducted “voluntary clinical trials,” trying the canine treatment on themselves in desperate hope. The medical industry had significant legal issues, including the Constitutional Court’s ruling that the 66-year-old anti-abortion law was unconstitutional. Hospitals suffered the worst shortage o
This year was a year where the word "safety" was particularly highlighted in the healthcare industry. The N-Nitrosodimethylamine (NDMA), a potentially carcinogenic substance, which caused a ruckus after being detected in valsartan-based antihypertensive treatment last year, was further extended to ranitidine and nizatidine. Earlier this month, the medical community was startled when the carcinogen
This year was a year where the word “safety” was particularly highlighted in the healthcare industry. The N-Nitrosodimethylamine (NDMA), a potentially carcinogenic substance, which caused a ruckus after being detected in valsartan-based antihypertensive treatment last year, was further extended to ranitidine and nizatidine. Earlier this month, the medical community was startled when the carcinogen